UK Biotech Completes Cancer-Focused Co. Buy In £17M Deal
Thalia Therapeutics PLC said Friday it has completed its acquisition of cancer treatments specialist Sanmirna, worth up to £16.7 million ($22.5 million)....To view the full article, register now.
Already a subscriber? Click here to view full article